Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
暂无分享,去创建一个
S. Shariat | I. Kovalszky | G. Kramer | K. Schmid | H. Reis | T. Szarvas | F. vom Dorp | S. Tschirdewahn | H. Rübben
[1] H. Klingler,et al. Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer. , 2012, Urology.
[2] J. Fischer,et al. High insulin‐like growth factor mRNA‐binding protein 3 (IMP3) protein expression is associated with poor survival in muscle‐invasive bladder cancer , 2012, BJU international.
[3] S. Ergün,et al. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer , 2012, International journal of cancer.
[4] G. Camussi,et al. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells , 2011, Leukemia.
[5] B. Vanhaesebroeck,et al. Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148 , 2011, Molecular biology of the cell.
[6] J. Couchman,et al. Transmembrane signaling proteoglycans. , 2010, Annual review of cell and developmental biology.
[7] Mitsutoshi Nakamura,et al. Role of syndecan‐1 (CD138) in cell survival of human urothelial carcinoma , 2010, Cancer science.
[8] I. Kovalszky,et al. Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer , 2009, Pathology & Oncology Research.
[9] Viktoriya D. Nikolova,et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. , 2009, Carcinogenesis.
[10] J. Couchman,et al. A Conserved NXIP Motif Is Required for Cell Adhesion Properties of the Syndecan-4 Ectodomain* , 2006, Journal of Biological Chemistry.
[11] I. Kovalszky,et al. Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. , 2006, Oral oncology.
[12] J. Stein,et al. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure , 2006, World Journal of Urology.
[13] T. Ørntoft,et al. Gene expression profiling of noninvasive primary urothelial tumours using microarrays , 2005, British Journal of Cancer.
[14] Y. Hiramatsu,et al. Prognostic significance of syndecan-1 expression in human endometrial cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[16] I. Sesterhenn,et al. World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .
[17] E. Dahl,et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. , 2004, European journal of cancer.
[18] A. Friedl,et al. Induction of Syndecan-1 Expression in Stromal Fibroblasts Promotes Proliferation of Human Breast Cancer Cells , 2004, Cancer Research.
[19] A. Rapraeger,et al. Syndecans in tumor cell adhesion and signaling , 2004, Reproductive biology and endocrinology : RB&E.
[20] T. Yoshizaki,et al. Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration* , 2003, Journal of Biological Chemistry.
[21] William C. Parks,et al. Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury , 2002, Cell.
[22] Heikki Joensuu,et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. , 2002, Cancer research.
[23] S. Groshen,et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Sobin,et al. World Health Organization classification of tumors , 2000, Cancer.
[25] Gillian Murphy,et al. Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase , 2000, The Journal of cell biology.
[26] A. Waage,et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. , 2000, Blood.
[27] P. Heikkilä,et al. Syndecan-1 expression has prognostic significance in head and neck carcinoma , 1999, British Journal of Cancer.
[28] B. Weyn,et al. Syndecan‐1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome , 1998, The Journal of pathology.
[29] Y. Kohgo,et al. Reduced expression of syndecan‐1 in human hepatocellular carcinoma with high metastatic potential , 1997 .
[30] K. Nackaerts,et al. Heparan sulfate proteoglycan expression in human lung‐cancer cells , 1997, International journal of cancer.
[31] Masato Kato,et al. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. , 1995, Molecular biology of the cell.
[32] J. Heino,et al. Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth. , 1992, The Journal of biological chemistry.
[33] D. Hanahan,et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma , 1991, Cell.
[34] A. Jemal,et al. Global Cancer Statistics , 2011 .
[35] A. Marx,et al. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .